Chest Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Amar, D.
Right arrow Articles by Fleisher, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Amar, D.
Right arrow Articles by Fleisher, M.
(Chest. 2001;119:1476-1479.)
© 2001 American College of Chest Physicians

Diltiazem Treatment Does Not Alter Renal Function After Thoracic Surgery*

David Amar, MD, FCCP and Martin Fleisher, PhD

* From the Department of Anesthesiology and Critical Care Medicine (Dr. Amar) and the Department of Clinical Laboratories (Dr. Fleisher), Memorial Sloan-Kettering Cancer Center, New York, NY.

Correspondence to: David Amar, MD, FCCP, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, Room M-304, New York, NY 10021; e-mail: amard{at}mskcc.org

Background: There are conflicting reports on the effects of diltiazem treatment on renal function in surgical patients. We sought to determine whether diltiazem treatment alters renal function in patients undergoing major thoracic surgery.

Methods: In a prospective study, 330 patients scheduled for elective thoracic surgery received either IV diltiazem (n = 167) or placebo (n = 163) immediately after the operation and orally thereafter for 14 days in an effort to prevent postoperative atrial arrhythmias. Serum creatinine and BUN levels were compared before and during the first postoperative week.

Results: Patients treated with diltiazem were similar to control subjects in terms of age (mean ±SD, 66 ± 10 years vs 67 ± 10 years, respectively), baseline serum creatinine or BUN levels, prevalence of comorbid conditions, and surgical characteristics. During the first 5 postoperative days, the two groups did not differ in terms of serum creatinine or BUN levels. The incidence of renal failure was 0.6% in the diltiazem group and 1.2% in the placebo group (difference was not significant). There was no difference in the length of hospitalization or mortality rate.

Conclusions: In patients without renal disease who are undergoing elective thoracic surgery, prophylactic diltiazem treatment did not alter postoperative renal function.

Key Words: diltiazem • renal function • surgery




This article has been cited by other articles:


Home page
 Ann. Thorac. Surg.Home page
S. Manabe, H. Tanaka, T. Yoshizaki, N. Tabuchi, H. Arai, and M. Sunamori
Effects of the Postoperative Administration of Diltiazem on Renal Function After Coronary Artery Bypass Grafting
Ann. Thorac. Surg., March 1, 2005; 79(3): 831 - 835.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the American College of Chest Physicians.